Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF Twisthaler versus fluticasone propionate + salmeterol in COPD
2008-000901-13Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol, mometasone, fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoints: Bronchodilator effect over 24 hours and Range of clinically meaningful bronchodilator endpoints. Started May 2008; status: completed.
02
Drugs
indacaterolmometasonefluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000901-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000901-13.